We are live on ! Find out more
XPH icon

State Street SPDR S&P Pharmaceuticals ETF

80 hedge funds and large institutions have $185M invested in State Street SPDR S&P Pharmaceuticals ETF in 2019 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more capital inflows, than outflows

Capital inflows: $70.3M | Capital outflows: $45.4M

38% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 16

18.28% more ownership

Funds ownership: 56.39% → 74.66% (+18%)

8% more funds holding

Funds holding: 74 → 80 (+6)

14% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 21

Holders
80
Holders Change
+6
Holders Change %
+8.11%
% of All Funds
1.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
18
Reduced
21
Closed
16
Calls
$981​K
Puts
–
Net Calls
+$981​K
Net Calls Change
+$395​K

XPH Hedge Fund Activity: Q1 2019 in Review

80 of the 4,635 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2019, worth a combined $185M — up 31% from $141M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new XPH positions and 16 closed out — a net gain of 6 holders — while 18 added to existing stakes and 21 trimmed.

The largest buyer was Credit Suisse, opening a new position worth an estimated $52.5M. The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $7.62M sold.

  • 80 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2019, up from 74 in Q4 2018.
  • Funds reported $185M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2019, up 31% quarter-over-quarter.
  • 22 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2019 and 16 closed out, a net change of +6 holders.
  • The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2019 was Credit Suisse, an estimated $52.5M added.
  • The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2019 was BNP Paribas Financial Markets, an estimated $7.62M sold.

Based on aggregated 13F filings for Q1 2019.